Ibrahim.A.B, Abdelbary.A, khowessah.O.M, and S. T. M., "Radioiodinated anastrozole and epirubicin as potential targeting radiopharmaceuticals for solid tumor imaging", J Radioanal Nucl Chem, vol. 303, pp. 967–975, 2015. omneya_paper.pdf
Al-mahallawi, A. M., O. M. Khowessah, and R. A. Shoukri, "Novel sustained release orally disintegrating tablet containing aceclofenac lipospheres: in-vitro and in-vivo studies", Inventi Rapid: Pharm Tech: Inventi Journals (P) Ltd, 2012. Abstract
n/a
Al–Gamrah, M. M., O. M. Khowessah, and A. A. Bary, "DEVELOPMENT OF AMLODEPINE BESYLATE FAST DISSOLVING CAPSULES BY ADOPTING LASER PERFORATION AND VACCUM DRYING TECHNIQUE", Inventi Impact: NDDS: Inventi Journals (P) Ltd, 2012. Abstract
n/a
Ghorab, D. M., M. M. Amin, O. M. Khowessah, and M. I. Tadros, "Colon-targeted celecoxib-loaded Eudragit® S100-coated poly-ε-caprolactone microparticles: preparation, characterization and in vivo evaluation in rats.", Drug delivery, vol. 18, issue 7, pp. 523-35, 2011 Sep-Oct. Abstract

CONTEXT: Celecoxib suffers from low and variable bioavailability following oral administration of solutions or capsules. Recent studies proved that chemoprevention of colorectal cancer is possible with celecoxib.

OBJECTIVE: This work aimed to tailor colon-targeted celecoxib-loaded microparticles using time-dependant and pH-dependant coats. Estimation of drug pharmacokinetics following oral administration to fasted rats was another goal.

METHODS: A 2³ factorial design was adopted to develop poly-ε-caprolactone (PCL) celecoxib-loaded microparticles (F1-F8). To minimize drug-percentages released before colon, another coat of Eudragit® S100 was applied. In vitro characterization of microparticles involved topography, determination of particle size and entrapment efficiency (EE %). Time for 50% drug release (t(₅₀%)) and drug-percentages released after 2 hours (Q(2h)) and 4 hours (Q(4h)) were statistically compared. Estimation of drug pharmacokinetics following oral administration of double-coat microparticles (F10) was studied in rats.

RESULTS: PCL-single-coat microparticles were spherical, discrete with a size range of 60.66 ± 4.21-277.20 ± 6.10 μm. Direct correlations were observed between surfactant concentration and EE%, Q(2h) and Q(4h). The PCL M.wt. and drug: PCL ratio had positive influences on EE% and negative impacts on Q(2h) and Q(4h). When compared to the best achieved PCL-single-coat microparticles (F2), the double-coat microparticles (F10) showed satisfactory drug protection; Q(2h) and Q(4h) were significantly (P < 0.01) decreased from 31.84 ± 1.98% and 54.72 ± 2.10% to 15.92 ± 1.78% and 26.93 ± 2.76%, respectively. When compared to celecoxib powder, F10 microparticles enhanced the bioavailability and extended the duration of drug-plasma concentration in rats.

CONCLUSION: The developed double-coat microparticles could be considered as a promising celecoxib extended-release colon-targeting system.

Al-mahallawi, A. M., O. M. Khowessah, and R. A. Shoukri, "Nano-transfersomal ciprofloxacin loaded vesicles for non-invasive trans-tympanic ototopical delivery: in-vitro optimization, ex-vivo permeation studies, and in-vivo assessment.", International journal of pharmaceutics, vol. 472, issue 1-2, pp. 304-14, 2014 Sep 10. Abstract

Ciprofloxacin is a synthetic fluoroquinolone antibiotic that has been used for systemic treatment of otitis media in adults. It was approved for topical treatment of otorrhea in children with tympanostomy tubes. The aim of this work was to enhance the local non-invasive delivery of ciprofloxacin to the middle ear across an intact tympanic membrane (TM) in an attempt to treat acute otitis media (AOM) ototopically. In order to achieve this goal, ciprofloxacin nano-transfersomal vesicles were prepared by thin film hydration (TFH) technique, using several edge activators (EAs) of varying hydrophilic-lipophilic balance (HLB) values. A full factorial design was employed for the optimization of formulation variables using Design-Expert(®) software. The optimal formulation was subjected to stability testing, ex-vivo permeation studies (through ear skin and TM of rabbits), and in-vivo evaluation. Results revealed that the optimal formulation (composed of phospholipid and sodium cholate as an EA at a molar ratio of 5:1) exhibited enhanced ex-vivo drug flux through ear skin and TM when compared with the commercial product (Ciprocin(®) drops). It demonstrated a greater extent of in-vivo drug deposition in the TM of albino rabbits relative to Ciprocin(®). Consequently, transfersomes could be promising for the non-invasive trans-tympanic delivery of ciprofloxacin.

El-Setouhy, D. A., A. B. Ibrahim, M. M. Amin, O. M. Khowessah, and E. S. Elzanfaly, "Intranasal haloperidol-loaded miniemulsions for brain targeting: Evaluation of locomotor suppression and in-vivo biodistribution.", European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, vol. 92, pp. 244-54, 2016 Sep 20. Abstract

Haloperidol is a commonly prescribed antipsychotic drug currently administered as oral and injectable preparations. This study aimed to prepare haloperidol intranasal miniemulsion helpful for psychiatric emergencies and exhibiting lower systemic exposure and side effects associated with non-target site delivery. Haloperidol miniemulsions were successfully prepared by spontaneous emulsification adopting 2(3) factorial design. The effect of three independent variables at two levels each namely; oil type (Capmul®-Capryol™90), lipophilic emulsifier type (Span 20-Span 80) and HLB value (12-14) on globule size, PDI and percent locomotor activity inhibition in mice was evaluated. The optimized formula (F4, Capmul®, Tween 80/Span 20, HLB 14) showed globule size of 209.5±0.98nm, PDI of 0.402±0.03 and locomotor inhibition of 83.89±9.15% with desirability of 0.907. Biodistribution study following intranasal and intravenous administration of the radiolabeled (99m)Tc mucoadhesive F4 revealed that intranasal administration achieved 1.72-fold higher and 6 times faster peak brain levels compared with intravenous administration. Drug targeting efficiency percent and brain/blood exposure ratios remained above 100% and 1 respectively after intranasal instillation compared to a maximum brain/blood exposure ratio of 0.8 post intravenous route. Results suggested the CNS delivery of major fraction of haloperidol via direct transnasal to brain pathway that can be a promising alternative to oral and parenteral routes in chronic and acute situations. Haloperidol concentration of 275.6ng/g brain 8h post intranasal instillation, higher than therapeutic concentration range of haloperidol (0.8 to 5.15ng/ml), suggests possible sustained delivery of the drug through nasal route.

Tourism